Description:

In April 2018, after a rigorous preregistered clinical trial that was published in the journal Nature Digital Medicine, the U.S. Food and Drug Administration (FDA) de novo authorized IDx-DR® the first autonomous AI system.  IDx-DR diagnoses (DR) and macular edema in adults who have diabetes and identifies those who need to be referred to eye care.   Two years later in November 2020, EyeArt® was 510k cleared by the FDA to market a similar device.  Based on claims data across all insured, only 15.3% of diabetic patients are receiving annual eye exams.  To tackle this gap in care, healthcare providers are implementing point-of-care tests utilizing autonomous AI technology to complete these diabetic retinal exams outside traditional eyecare settings.  This continuing education will not only reveal how AI technology is changing the way DR and macular edema are identified, but it will also help optometrists prepare for this rapidly evolving healthcare delivery model.

Course Code:

AOA223-PB

Speaker(s):

Dana Weitzman, O.D.
dena.weitzman@gmail.com

Credits:

1

AOA Expiration Date:

3/3/2025

Related News

Surveys say patient and doctor concerns about health industry middlemen on the rise

Insurers, vision benefit managers and their abuses represent “what’s wrong” with health care, fresh indicators show.

Optometry’s Meeting® gives students, recent grads a leg up in the field

At Optometry’s Meeting® in Minneapolis, June 25-28, attendees can tackle the job market by leveraging cutting-edge educational and networking opportunities with other students and colleagues from around the world.

Inspiring optometry’s next generation

Tessa Sokol, O.D., explains why recruiting the best and brightest into our profession isn’t just beneficial—it’s essential for the future of optometry.